Abstract
ObjectiveThis study aimed to examine the types of sales strategies used by pharmaceutical companies in a “pharmerging” market and to gain insight into the ways of avoiding the negative effects of these strategies. MethodIn-depth interviews were conducted with 22 physicians and company employees in the six largest cities of Turkey. The interviews were analyzed using content analysis. ResultsVarious sales strategies, both legal and illegal, are universally applied. These methods target prescribers, patients, pharmacists, and society in general. Different types of companies, organizations, professionals, and science and ethical principles are used as means. Companies intervene immediately to prevent developments that may decrease sales, and exploit the educational and infrastructural needs. In contrast, physicians are overconfident about the effects of marketing and insufficiently educated on how to cope with the strategies and the drugs on the market, which make them vulnerable. Under these conditions, along with worldwide competition and economic volatility, policies that aim to set frameworks for pharmaceutical relationships have failed. ConclusionInterventions are crucial, including instituting a national drug policy, minimizing the exposure to marketing, and addressing the educational and infrastructural needs of the prescribers. Without these interventions, gaps will continue to be exploited by companies for their own advantage, and the problems related to marketing will persist.
Highlights
the purpose of this article is to study the current state of the pharmaceutical industry in Russia
the study is based on a quantitative study of the characteristics and trends
The emphasis was put on the period 2008–2017
Summary
Составлено автором по материалам DSM Group: URL: http://www.dsm.ru/marketing/free-information/analytic-reports/ Рис. 1 показаны результаты SWOT-анализа состояния фармацевтической отрасли России в 2017 заметны Инновационное развитие отрасли требует отдельной системной программы в рамках общей поддержки науки в России, которая существенно недофинансируется в сравнении с развитыми странами мира.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.